<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00831337</url>
  </required_header>
  <id_info>
    <org_study_id>PAM 12/06/PB</org_study_id>
    <nct_id>NCT00831337</nct_id>
  </id_info>
  <brief_title>Evaluation of Probiotics in the Treatment of Portal Hypertension</brief_title>
  <official_title>The Study of Probiotics in Liver Cirrhosis Patients With Portal Hypertension.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pomeranian Medical University Szczecin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pomeranian Medical University Szczecin</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate the role of probiotics in the treatment of portal hypertension. In
      particular the role of probiotics on gut microbiota in liver cirrhosis patients will be
      studied and compared with cytokines and other substances implicated in the pathogenesis of
      portal hypertension. The hypothesis whether probiotics may change the prognosis of patients
      with portal hypertension will be studied. The hypothesis whether probiotics may halt the
      pathologic cascade of events leading to various complications (e.g. hepato-renal syndrome,
      spontaneous bacterial peritonitis, bleeding varices) will be reviewed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Studied probiotics: VSL3
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Laboratory data</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical and laboratory data</measure>
    <time_frame>1 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Liver Cirrhosis</condition>
  <condition>Portal Hypertension</condition>
  <condition>Encephalopathy</condition>
  <arm_group>
    <arm_group_label>Liver cirrhosis compensated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VSL3 supplemented twice daily for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Liver cirrhosis decompensated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VSL3 supplemented twice daily for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VSL3 supplemented twice daily for 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>VSL3</intervention_name>
    <description>2 times daily 450 billion live bacteria (in each saschet)</description>
    <arm_group_label>Liver cirrhosis compensated</arm_group_label>
    <arm_group_label>Liver cirrhosis decompensated</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed liver cirrhosis (liver biopsy or typical imaging studies)

          -  Confirmed portal hypertension

          -  18 years and older

          -  compliant patients

        Exclusion Criteria:

          -  Antibiotic treatment in last 3 months

          -  Lactulose treatment in last 3 months

          -  Patients taking NSAIDS in lat 3 months

          -  Steroid treatment in last 3 months

          -  Ongoing and active infection

          -  Pregnant woman

          -  Cancer diagnosis

          -  decompensated diabetes mellitus

          -  active or past treatment with recombinant cytokines (e.g. anty TNF, interferon etc)

          -  medication altering function of CNS, suffering from neurological or ophthalmological
             conditions

          -  initiating the therapy with beta blockers within the prior 12 weeks

          -  mental disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wojciech M Marlicz, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pomeranian Medical University Szczecin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Gastroenterology, Pomeranian Medical University</name>
      <address>
        <city>Szczecin</city>
        <zip>71-252</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 27, 2009</study_first_submitted>
  <study_first_submitted_qc>January 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2009</study_first_posted>
  <last_update_submitted>November 21, 2016</last_update_submitted>
  <last_update_submitted_qc>November 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Pomeranian Medical University Szczecin</investigator_affiliation>
    <investigator_full_name>Wojciech Marlicz</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <keyword>VSL3</keyword>
  <keyword>Probiotics</keyword>
  <keyword>Gut microbiota</keyword>
  <keyword>Cytokines</keyword>
  <keyword>Portal hypertension</keyword>
  <keyword>Chemokines</keyword>
  <keyword>Liver cirrhosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Hypertension, Portal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

